Mycoplasma Testing Market held USD 689 USD million in 2020 and is to grow with a CAGR of 9.1% from 2021-2030. Mycoplasma testing is a group of tests that either detect the microbe directly by culture or by identifying its genetic material (DNA) in bodily samples, or assess antibodies in the blood generated in reaction to a mycoplasma infection. The most typical example is for the detection of Mycoplasma pneumonia.
Market Dynamics and Factors:
The increasing prevalence of COVID-19 infections around the globe coupled with a surge in demand for detecting the mycoplasma testing for detecting and diagnosing the number of infection cases and antibody response to the coronavirus has impelled the market growth. For instance, according to the Worldometer Information in May 2021, globally more than 175.17 Million Covid-19 people have been diagnosed and over 3.7 million people have been died due to COVID-19 infection. It created a massive demand for the mycoplasma testing market.
Increasing funding for conducting the research activities in the pharmaceutical & biopharmaceutical industries with the surge in government initiatives, increasing demand for fast, accurate, and affordable testing, and rise in cell culture contamination have witnessed potential demand for the mycoplasma testing market growth. For instance, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA)) the report, the global pharmaceutical market was valued at approximately USD 1.4 Trillion billion in 2020 and is expected to reach USD 1,580 billion in 2022.
Market Segmentation:
The mycoplasma testing market was led by the Kits & reagents segment as it provides rapid, an ultrasensitive and simple fluorescence microscopic assay for the visual identification of mycoplasma testing infection in laboratory cell cultures.
Geographic Analysis:
North America dominated the mycoplasma testing market and held the greatest revenue share in 2020 due to the presence of several leading pharmaceutical players and surge in the prevalence of infectious diseases and growing pharmaceutical research and development activities spending. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), United State’s leading pharmaceutical activities accounted for USD 75 billion which is more than half of the global research & development spending in pharmaceuticals. It created a massive demand for the growth of the mycoplasma testing market.
Competitive Scenario:
To enhance mycoplasma testing market share, prominent companies are likely to use different techniques such as product launches and acquisitions. For instance, in March 2021,Thermo Fisher has partnered with Artificial to enhance COVID-19 diagnostics testing solutions. Also, in Feb, 2021, Thermo Fisher has completed the acquisition of Mesa Biotech Inc., a molecular diagnostic company. It created massive demand for the growth of the mycoplasma testing market growth.
Mycoplasma Testing Market Report Scope
| Report Attribute | Details |
| Analysis Period | 2020–2030 |
| Base Year | 2021 |
| Forecast Period | 2022–2030 |
| Market Size Estimation | Billion (USD) |
| Growth Rate (CAGR%) | 9.1 % |
|
| By Product (Kits & Reagents, Instruments, Services, and Others), By Technology (ELISA, Direct Assay, Indirect Assay, Enzymatic Methods, Microbial Culture Techniques, and Others), Application (Virus Testing, Cell Line Testing, End of Production Cells Testing, and Others) |
| Geographical Segmentation | North America (U.S., Canada, Mexico) Europe (UK, Germany, Italy, France, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Rest of APAC), South America (Brazil, Argentina, Rest of SA), MEA (UAE, Saudi Arabia, South Africa) |
| Key Companies Profiled | Thermo Fisher Scientific, Inc.,Lonza Group Ltd.,NorgenBiotek Corp.,Merck KGaA,Biological Industries Israel Beit ,Roche Diagnostics,NorgenBiotek Corp.,Minerva Biolabs GmbH,InvivoGen,PromoCell GmbH |
